ABSTRACT Background: There is significant histologic and biochemical overlap between nonalcoholic fatty liver disease (NAFLD) and steatohepatitis associated with choline deficiency. Objective: We sought to determine whether subjects with biopsyproven NAFLD and evidence of an inadequate intake of choline had more severe histologic features. Design: We performed a cross-sectional analysis of 664 subjects enrolled in the multicenter, prospective Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) with baseline data on diet composition (from a recall-based food-frequency questionnaire) within 6 mo of a liver biopsy. Food questionnaires were analyzed with proprietary software to estimate daily intakes of choline. Liver biopsies were centrally read, and consensus was scored with the NASH CRN-developed scoring system. Because choline needs vary by age, sex, and menopausal status, participants were segregated into corresponding categories (children 9-13 y old, males 14 y old, premenopausal women 19 y old, and postmenopausal women) on the basis of the Institute of Medicine's definition of adequate intake (AI) for choline. Deficient intake was defined as ,50% AI. Results: Postmenopausal women with deficient choline intake had worse fibrosis (P = 0.002) once factors associated with NAFLD (age, race-ethnicity, obesity, elevated triglycerides, diabetes, alcohol use, and steroid use) were considered in multiple ordinal logistic regression models. Choline intake was not identified as a contributor to disease severity in children, men, and premenopausal women. Conclusion: Decreased choline intake is significantly associated with increased fibrosis in postmenopausal women with NAFLD. The Pioglitazone vs Vitamin E vs Placebo for Treatment of NonDiabetic Patients With Nonalcoholic Steatohepatitis trial was registered at clinicaltrials.gov as NCT00063622, and the Treatment of Nonalcoholic Fatty Liver Disease in Children trial was registered at clinicaltrials.gov as NCT00063635.
INTRODUCTION
The spectrum of NAFLD 4 includes NASH, which is an inflammatory process with accompanying hepatocellular necrosis and subsequent fibrosis. NASH can progress to cirrhosis and liver failure and is associated with an increased risk of development of hepatocellular carcinoma (1-3). Current estimates place the prevalence of NAFLD in the general US population at 1 in 3 people, whereas 1 in 20 people have NASH (2, 3) . Progression to steatohepatitis is not imminent or absolute in all patients with NAFLD. A second insult may be necessary for the activation of proinflammatory pathways that results in the development of a chronic inflammatory reaction in a liver rendered vulnerable by the accumulation of fat (4) (5) (6) .
In one animal model of steatohepatitis, rodents that consumed a high-fat, methionine and choline-deficient diet developed steatosis with inflammation and hepatic necrosis with the eventual development of hepatocellular carcinoma. Some strains of mice also manifest hepatic fibrosis. Hepatic fibrosis also developed in rodents that consumed a choline and B-12-deficient diet as well as a choline-deficient diet alone, although histologic changes developed more slowly. Although the liver histology of rodents on a methionine and choline-deficient diet may be similar to that with NASH, the overall phenotype of these mice is significantly different because they tend to lose weight on this diet and are not insulin resistant (7) (8) (9) (10) (11) (12) .
Choline is a quaternary amine present in all mammalian tissues. Foods high in choline include dairy, liver, eggs, legumes, nuts, beef, leafy greens, seed oils, and grain germs (13) . Choline is an essential component of cell membranes and is required for the synthesis of phospholipids. Choline is a precursor for the neurotransmitter acetylcholine and serves as a methyl group donor (14). Despite endogenous pathways for choline synthesis (15) , humans on a low-choline diet will develop choline deficiency (16) . Furthermore, humans on long-term parenteral nutrition that lacks adequate choline will show a reversal of hepatic steatosis and a decrease in serum aminotransferases with choline supplementation. The pathologic changes return with the cessation of choline supplementation (17, 18) .
In addition to age-and sex-dependent differences in choline requirements (14), there is also a differential susceptibility to choline deficiency that is based on menopausal status. Premenopausal women are less likely to develop hepatic steatosis or an elevation of their aspartate aminotransferase or alanine aminotransferase than either men or postmenopausal women (19) . This differential response has been hypothesized to arise from an estrogen-response element in the upstream region of the PEMT gene, which is an enzyme in one of the choline biosynthetic pathways (20) . Genome-association studies have demonstrated susceptibility to choline deficiency with single nucleotide polymorphisms in this gene (20) (21) (22) . It has also been shown that PEMT gene expression and enzyme activity are inducible on estrogen exposure in mouse and human hepatocytes (23) .
Given the histologic overlap between choline deficiencyassociated steatohepatitis and NASH, we hypothesized that individuals with a limited intake of choline may demonstrate more severe histologic changes.
SUBJECTS AND METHODS

Subjects
Subjects were enrolled in one of following 3 studies of the NASH CRN (24) : 1) the NAFLD Database (observational cohort) (25) , 2) the randomized, placebo control trial for Pioglitazone vs Vitamin E vs Placebo for Treatment of Non-Diabetic Patients With Nonalcoholic Steatohepatitis (www.clinicaltrials. gov; NCT00063622) (26, 27) , and 3) the Treatment of Nonalcoholic Fatty Liver Disease in Children (www.clinicaltrials. gov; clinical trial number NCT00063635) (28, 29) . See Table 1 under "Supplemental data" in the online issue for a summary of patient selection and inclusion and exclusion criteria. The NASH CRN consists of 8 clinical centers and a central data coordinating center. Laboratory studies were drawn within 6 mo of screening, and biopsies were obtained within 1 y of screening. Patients enrolled with baseline data on diet composition (detailed in "Dietary intake" below) within 180 d of a liver biopsy were included. Subjects with significant alcohol consumption (.20 g/d for women and .30 g/d for men, either currently or for a period of .3 consecutive months in the 5 y before screening) or who were unable to reliably quantify alcohol intake were excluded.
Ethics
All study protocols were approved by the institutional review boards of the participating centers. All participants provided written informed consent and assent, if applicable.
Patient baseline data and histology
Baseline data regarding demographics, anthropometric measures, and laboratory data were obtained as previously described (30) . Postmenopausal patients were self-identified as part of the entry questionnaire. Liver biopsies were centrally read, and consensus was scored with the NASH CRN scoring system (31 
Dietary intake
Dietary data were collected with the Block Food Questionnaire (adults) or Brief Food Questionnaire (children) (NutritionQuest) (32) (33) (34) (35) (36) , which are recall-based food inventories regarding eating habits over the past year. The questionnaires were completed at enrollment and analyzed with NutritionQuest proprietary software (NutritionQuest) to provide daily intakes of choline and betaine in milligrams per day. Choline and betaine contents of specific foods that were used to score the food-frequency questionnaire were obtained from the USDA Database for the Choline Content of Common Foods, Release 2 (37). An additional analysis was performed to provide daily intake of calories, carbohydrates, protein, fat, vitamin B-12, and folate.
Statistics
Participants were divided into categories corresponding to the Institute of Medicine's definition of AI for choline ( Table 1) . Deficient intake was defined as intake less than one-half of the AI (14) for each group as follows: children 9-13 y old (,188 mg/d), males 14 y old (,275 mg/d), adolescent females 14-18 y old (,200 mg/d), and women 19 y old (,212 mg/d). Children ,9 y old (n = 13) and adolescent females 14-18 y old (n = 18) were excluded because of insufficient numbers. Because postmenopausal women are more likely to develop fatty liver with choline deprivation (19) , adult women were subdivided into premenopausal and postmenopausal categories. For analyses, patients were classified as Hispanic (any race), white (nonHispanic), or other. Correlations for measured variables were calculated by Spearman's rank correlation. P values were calculated by using the Kruskal-Wallis test for categorical variables and the t test for Spearman's rank correlation for measured variables. Multiple ordinal logistic regression models in which known contributors to NAFLD and NASH were controlled for were constructed to compare the calculated daily choline intake to the steatosis grade and fibrosis stage. Steatosis was categorized as ,34%, 34-66%, .66% of low-to medium-power ) (yes compared with no), alcohol use, and steroid use were adjusted for in regression analyses. Total caloric intake was also adjusted for in both models for decreased overall intake. The proportional odds assumption for multiple ordinal logistic regression models was assessed by using the score test. Because the score test showed a violation of the assumption in one model, additional analyses were conducted by using the Brant test to assess the proportional odds for individual variables. The primary variable of interest (ie, daily choline intake) was shown to meet the assumption.
Because choline deficiency may be unmasked in a folatesufficient/B-12-deficient state because of interactions between the pathways for choline, vitamin B-12, and folate metabolism (38, 39) , reported B-12 and folate intakes calculated from the dietary questionnaire were included as a separate variable in the multiple logistic regression along with an interaction variable between the included vitamins and choline. For postmenopausal women, a second model with HRT adjusted for was performed in addition to the previously mentioned parameters.
All statistical analyses were performed with SAS for Windows (version 9.1; SAS Institute Inc) and STATA (version 10; StataCorp).
RESULTS
Baseline characteristics
Six hundred sixty-four patients were included in this study. Baseline characteristics are listed in Table 2 . Whites composed the greatest percentage of each group (66% males 14 y old; 70% premenopausal women 19 y old; 83% postmenopausal women), except for children 13 y old, of whom the majority were self-classified as Hispanic (59%). The proportion of subjects in the steatosis and fibrosis categories was analyzed by race-ethnicity, and there was no difference in the distribution by using Fisher's exact test except in the fibrosis categories for males 14 y old. The median BMI for all adult and adolescent groups was classified as obese, whereas for children, the median BMI z score was . (compared with 425 mg/d AI). The median reported intakes of vitamin B-12 and folate were greater than the Recommended Daily Allowance for all groups. The percentage of participants who had any alcohol intake (but less than the cutoff for study eligibility, as previously described) was highest in premenopausal women 19 y old (56%), followed by in males 14 y old (50%), postmenopausal women (47%), and children 13 y old (0%). The daily caloric intake was lowest in postmenopausal women (1562 calories), followed by in premenopausal women (1576 calories), children (1789 calories), and males (1903 calories), with daily intakes of protein that followed a similarly ranked order as follows: postmenopausal women: 58.5 g; premenopausal women: 61.7 g; children: 71.9 g; and males: 75.8 g. Carbohydrate intake followed a different pattern, with the most carbohydrates consumed by children (234 g) followed by males (227 g), premenopausal women (193 g), and postmenopausal women (187 g). The daily fat intake was highest in males (80 g), whereas children and pre-and postmenopausal women all consumed approximately equal amounts of daily fat (;66 g). Details of biopsy histologies of participants are shown in Table 3 . The greatest percentage of high-grade (.66%) steatosis was seen in children (42%) compared with in only 26% of males 14 y old, 32% of premenopausal women 19 y old, and 24% of postmenopausal women. Most participants showed little lobular inflammation, but fibrosis was common; 79% of postmenopausal women had fibrosis as did 76% of children 13 y old, 67% of males 14 y old, and 70% of premenopausal women 19 y old. Cirrhosis was shown in 12% of postmenopausal women, whereas only 0.9% of children 13 y old, 5% of males 14 y old, and 1.7% of premenopausal women 19 y old had cirrhosis.
Correlation with reported choline intake
Associations of baseline data and histology with choline intake are detailed in Tables 4 and 5 . Choline intake, which was unadjusted for other variables, was not significantly associated with the NAFLD activity score, steatosis, lobular inflammation, ballooning, or fibrosis in any group. Choline intake differed by race-ethnicity for children and males 14 y old. For males 14 y old, whites had the highest choline intake (327 mg/d) followed by subjects who were self-classified of more than one race (297 mg/d), Hispanic (277 mg/d), and other (230 mg/d) (P = 0.001). In children, subjects of more than one race consumed the most choline (716 mg/d), followed by Hispanic (311 mg/d), other (309 mg/d), and white (274 mg/d) races (P = 0.03). Choline intake for premenopausal women increased with BMI (P = 0.008; Spearman's rank correlation coefficient = 0.25). There was a significant correlation between choline intake and calories, protein, fat, and carbohydrates (P , 0.0001 for all comparisons in all groups).
Ordinal logistic regression
The breakdown of subjects in each of the age and menopausal status groups into fibrosis and steatosis categories by reported choline-intake status is detailed in Table 6 . These data were analyzed by using ordinal logistic regression models constructed to account for known contributors to the development of NASH/ NAFLD including age, race-ethnicity, obesity (especially central obesity) hypertriglyceridemia, diabetes and insulin resistance, daily caloric intake, alcohol use, and steroid use. Results are summarized in Table 7 . Subjects with deficient reported choline intakes did not have worse steatosis in any analysis group. The analysis of fibrosis stage showed that postmenopausal women with a reported choline intake less than one-half the defined AI had more significant fibrosis after known contributors to NASH/ NAFLD were controlled for (P = 0.002). To further investigate the association between reported choline intakes and fibrosis stages in postmenopausal women, additional ordinal logistic regression models were constructed that contained only the reported choline intake and one other term. The model that used Hb A 1c had the most significant P value (P = 0.008). Other terms leading to significant P values were BMI (P = 0.03), HOMA-IR (P = 0.03), and waist circumference (P = 0.03).
Additional ordinal logistic regression models were constructed with adjustment for vitamin B-12 and folate intakes. These models included an interaction term for choline and either vitamin B-12 or folate. No significant change in any association was shown by including these additional vitamins, and none of the interaction terms reached significance. Similarly, given the association with estrogen status and susceptibility to choline deficiency, an additional model that incorporated HRT was constructed for the postmenopausal group. The number of postmenopausal women who took any kind of HRT was 27% (53 of 194 women). The association of worse fibrosis with decreased choline intake was not affected by the inclusion of this term. 
DISCUSSION
NASH is the major cause of cryptogenic cirrhosis (40) . The process is likely multifactorial but has known associations with obesity (41-45), insulin resistance (26, (46) (47) (48) , and hyperlipidemia (49) (50) (51) . Given these associations, a nutritional contribution to the development of NAFLD and NASH has attracted significant attention with multiple micronutrients that showed an association (52, 53) . We sought to determine whether an association exists between choline intake and histologic severity of NAFLD or NASH. Remarkably, we showed that postmenopausal women with NASH and a daily calculated choline intake less than onehalf the defined AI exhibited worse fibrosis. Choline was previously thought to be nonessential; however, it is now known that healthy humans are unable to synthesize enough choline de novo to prevent deficiency (16) . In addition, patients on long-term parenteral nutrition with steatohepatitis who are choline deficient show reversal of steatohepatitis with supplementation of choline (17, 18) . Also, individuals with specific polymorphisms in genes involved in the choline pathway have altered susceptibility to choline deficiency (20, 54) ; subjects with V175M substitution in the PEMT protein, which is an enzyme in one of the choline biosynthetic pathways, show increased susceptibility to develop NAFLD, commonly without obesity (55) . Of note, the promoter region of the PEMT gene contains a polymorphism that increased susceptibility to choline deficiency in postmenopausal women (20) who, then, were vulnerable to develop fatty liver when placed on a severely choline deficient diet (,10% AI) in clinical trials (19) . The current study considered intakes ,50% AI deficient. Although it did not reach statistical significance, we showed the same trend in both premenopausal women and men. These findings, coupled with the results of clinical trials, may suggest that men have additional mechanisms of upregulating genes in the choline synthesis pathway that are able to compensate for moderate deficiencies but not severe deficiencies. Other genes, including PNPLA3, also appear to play an important role in the development of NAFLD and have been shown to be associated with both increased hepatic fat amounts and fibrosis (56, 57) .
Although we expected to see an increase in steatosis with decreased choline intakes, the relative lack of steatosis suggested that other contributing factors outweigh choline deficiency for deposition of fat, the progression to fibrosis is faster in a choline- deficient state (and, thus, the stage that shows increased steatosis is missed by the biopsy protocol used in these studies), or dietary choline deficiency only plays a role in advanced stages of liver disease accompanied by an impaired ability to synthesize choline, because cirrhotic patients have decreased ability to synthesize choline de novo (58) . A fourth possibility is that patients enrolled in the studies already had histologic evidence of NAFLD or NASH, or, at the very least, a strong suspicion of either. In this population, the disease stage at which steatosis is hypothesized to be hastened by choline deficiency may have already passed, or alternatively, some threshold level of choline deficiency may cause steatosis, but more severe deficiency may not cause additional increases in steatosis. Our study was limited by its cross-sectional nature. We obtained a dietary history only at enrollment in the study, and dietary choline intake was not validated by plasma concentrations. The dietary history was recall based and required participants to select from a predefined list of foods with an estimated frequency of intake. The recall-based nature may have led to an underestimation of intakes. For example, the total caloric intake for adults in the study averaged ,2000 calories/d, whereas BMI was .33. Furthermore, the preprinted list of foods may not have captured the dietary subtleties of ethnic diets of some subjects. Last, we did not genotypes these subjects. The variation in genes known to affect the choline synthesis pathway may more specifically identify individuals susceptible to choline deficiency or for whom choline supplementation may have a beneficial effect (20) (21) (22) (54) (55) (56) (57) .
A previous study in 47 patients did not find a correlation between plasma choline concentration and the severity of liver damage in NASH (59) . Because NASH is the presumed end result of multiple pathways with behavioral, environmental, and genetic contributions, choline deficiency may play a role in only a subset of patients with NAFLD or NASH. Pure choline deficiency may only become apparent in an appropriately selected phenotypic subset of NASH patients, such as in postmenopausal women who may be unable to upregulate genes in the choline synthesis pathway that have estrogen-response elements in their promoters (23) .
In conclusion, decreased choline intake is associated with worse fibrosis in a subset of patients with NASH. Additional study is needed to determine whether a reported low choline intake is associated with low plasma choline concentrations and if low choline concentrations are associated with the initiation or progression of NAFLD or NASH. 1 All values are cumulative ORs; 95% CIs in parentheses. The cumulative OR of worse steatosis or fibrosis associated with a deficient daily choline intake (less than one-half the defined ADI) was assessed by using an ordinal logistic regression model with known contributors to NAFLD and NASH controlled for. ORs and P values were derived from multiple ordinal logistic regression models. Dietary choline was analyzed as a dichotomous variable, whereby choline values less than the deficient intake concentration were compared with values greater than or equal to deficient intake. Values of deficient choline intake are specific to each group.
2 Defined as ,34%, 34-66%, and .66%. 
